After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NYSE-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ginkgo Bioworks Holdings Inc is $2.22B. A total of 16.96 million shares were traded on the day, compared to an average of 22.73M shares.
In the most recent transaction, Dmytruk Mark E. sold 38,826 shares of DNA for 1.26 per share on Mar 04 ’24. After the transaction, the insider now owns 808,125 company shares. In a previous transaction on Feb 02 ’24, Dmytruk Mark E. sold 39,569 shares at 1.21 per share. DNA shares that the insider owns now total 761,737.
Among the insiders who sold shares, Kelly Jason R disposed of 100,000 shares on Jan 04 ’24 at a per-share price of $1.55. This resulted in the insider holding 3,894,680 shares of DNA after the transaction. In another insider transaction, Kelly Jason R sold 100,000 shares at $1.54 per share on Jan 03 ’24. Company shares held by the insider now total 3,994,680.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, DNA has a high of $2.55 and a low of $1.03.
As of this writing, DNA has an earnings estimate of -$0.08 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.08 per share and a lower estimate of -$0.1. The company reported an EPS of -$0.16 in the last quarter, which was -77.80% lower than expectations of -$0.09.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $0.58, while its Total Shareholder’s Equity was $1.57B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 2.86.
